Another major obstacle is the frequent compensatory activation of alternative signaling pathways or kinases, which often prevents the therapeutic effect of PTK inhibitors by allowing tumor cells to escape their dependency on the targeted PTK. The gene discussed is PTK2B; the disease is neoplasm.